The diagnosis and treatment of soft tissue sarcomas (STSs), including gastrointestinal stromal tumours (GISTs), has seen great progress in recent years. A new World Health Organization (WHO) classification was published this year and several novel drugs have shown activity in subsets of sarcoma and GIST. In addition to sarcoma and GIST, the book also provides information about diagnosis and therapy of cancer of unknown primary site (CUP), with an emphasis on the value of gene-profiling microarray diagnosis in this indication.
This first edition of Sarcoma and Gastrointestinal Stromal Tumours plus Cancer of Unknown Primary Site: Essentials for Clinicians encompasses the whole spectrum of current knowledge and provides clinicians with an easily accessible overview as well as a focus on key developments in the treatment of STS, GIST and CUP. The topics range from pathology to the current therapeutic options in these indications.
Sarcoma, representing <2% of all tumours with >50 different subtypes, is a true (ultra) rare condition that should be treated under the guidance of reference centres to ensure quality of care. For this reason, in Europe, EURACAN was founded. This network of hospitals includes all rare cancers including STS and GIST.
Concise text together with many colour illustrations provide the reader with a simple and engaging way to acquire information. Under our editorial supervision, all chapters have been contributed by experts in sarcoma, GIST and CUP, highly regarded in their field.
Professor Iwona Lugowska
Warsaw, Poland
Professor Jean-Yves Blay
Lyon, France
Professor Hans Gelderblom
Leiden, Netherlands
